Cargando…

Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data

PURPOSE: Oncotype DX (ODX) recurrence score (RS) breast cancer (BC) assay is costly, and performed in only ~1/3 of estrogen receptor (ER)-positive BC patients in the USA. We have now developed a user-friendly nomogram surrogate prediction model for ODX based on a large dataset from the National Canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Orucevic, Amila, Bell, John L., McNabb, Alison P., Heidel, Robert E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5387031/
https://www.ncbi.nlm.nih.gov/pubmed/28243897
http://dx.doi.org/10.1007/s10549-017-4170-3
_version_ 1782520863312052224
author Orucevic, Amila
Bell, John L.
McNabb, Alison P.
Heidel, Robert E.
author_facet Orucevic, Amila
Bell, John L.
McNabb, Alison P.
Heidel, Robert E.
author_sort Orucevic, Amila
collection PubMed
description PURPOSE: Oncotype DX (ODX) recurrence score (RS) breast cancer (BC) assay is costly, and performed in only ~1/3 of estrogen receptor (ER)-positive BC patients in the USA. We have now developed a user-friendly nomogram surrogate prediction model for ODX based on a large dataset from the National Cancer Data Base (NCDB) to assist in selecting patients for which further ODX testing may not be necessary and as a surrogate for patients for which ODX testing is not affordable or available. METHODS: Six clinicopathologic variables of 27,719 ODX-tested ER+/HER2−/lymph node-negative patients with 6–50 mm tumor size captured by the NCDB from 2010 to 2012 were assessed with logistic regression to predict high-risk or low-risk ODXRS test results with TAILORx-trial and commercial cut-off values; 12,763 ODX-tested patients in 2013 were used for external validation. The predictive accuracy of the regression model was yielded using a Receiver Operator Characteristic analysis. Model fit was analyzed by plotting the predicted probabilities against the actual probabilities. A user-friendly calculator version of nomograms is available online at the University of Tennessee Medical Center website (Knoxville, TN). RESULTS: Grade and progesterone receptor status were the highest predictors of both low-risk and high-risk ODXRS, followed by age, tumor size, histologic tumor type and lymph-vascular invasion (C-indexes-.0.85 vs. 0.88 for TAILORx-trial vs. commercial cut-off values, respectively). CONCLUSION: This is the first study of this scale showing confidently that clinicopathologic variables can be used for prediction of low-risk or high-risk ODXRS using our nomogram models. These novel nomograms will be useful tools to help physicians and patients decide whether further ODX testing is necessary and are excellent surrogates for patients for which ODX testing is not affordable or available. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10549-017-4170-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5387031
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-53870312017-04-27 Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data Orucevic, Amila Bell, John L. McNabb, Alison P. Heidel, Robert E. Breast Cancer Res Treat Preclinical Study PURPOSE: Oncotype DX (ODX) recurrence score (RS) breast cancer (BC) assay is costly, and performed in only ~1/3 of estrogen receptor (ER)-positive BC patients in the USA. We have now developed a user-friendly nomogram surrogate prediction model for ODX based on a large dataset from the National Cancer Data Base (NCDB) to assist in selecting patients for which further ODX testing may not be necessary and as a surrogate for patients for which ODX testing is not affordable or available. METHODS: Six clinicopathologic variables of 27,719 ODX-tested ER+/HER2−/lymph node-negative patients with 6–50 mm tumor size captured by the NCDB from 2010 to 2012 were assessed with logistic regression to predict high-risk or low-risk ODXRS test results with TAILORx-trial and commercial cut-off values; 12,763 ODX-tested patients in 2013 were used for external validation. The predictive accuracy of the regression model was yielded using a Receiver Operator Characteristic analysis. Model fit was analyzed by plotting the predicted probabilities against the actual probabilities. A user-friendly calculator version of nomograms is available online at the University of Tennessee Medical Center website (Knoxville, TN). RESULTS: Grade and progesterone receptor status were the highest predictors of both low-risk and high-risk ODXRS, followed by age, tumor size, histologic tumor type and lymph-vascular invasion (C-indexes-.0.85 vs. 0.88 for TAILORx-trial vs. commercial cut-off values, respectively). CONCLUSION: This is the first study of this scale showing confidently that clinicopathologic variables can be used for prediction of low-risk or high-risk ODXRS using our nomogram models. These novel nomograms will be useful tools to help physicians and patients decide whether further ODX testing is necessary and are excellent surrogates for patients for which ODX testing is not affordable or available. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10549-017-4170-3) contains supplementary material, which is available to authorized users. Springer US 2017-02-27 2017 /pmc/articles/PMC5387031/ /pubmed/28243897 http://dx.doi.org/10.1007/s10549-017-4170-3 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Preclinical Study
Orucevic, Amila
Bell, John L.
McNabb, Alison P.
Heidel, Robert E.
Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
title Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
title_full Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
title_fullStr Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
title_full_unstemmed Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
title_short Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
title_sort oncotype dx breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
topic Preclinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5387031/
https://www.ncbi.nlm.nih.gov/pubmed/28243897
http://dx.doi.org/10.1007/s10549-017-4170-3
work_keys_str_mv AT orucevicamila oncotypedxbreastcancerrecurrencescorecanbepredictedwithanovelnomogramusingclinicopathologicdata
AT belljohnl oncotypedxbreastcancerrecurrencescorecanbepredictedwithanovelnomogramusingclinicopathologicdata
AT mcnabbalisonp oncotypedxbreastcancerrecurrencescorecanbepredictedwithanovelnomogramusingclinicopathologicdata
AT heidelroberte oncotypedxbreastcancerrecurrencescorecanbepredictedwithanovelnomogramusingclinicopathologicdata